RECRUITING

Ovarian Tissue Cryopreservation for Fertility Preservation

Conditions

Cancer Autoimmune Diseases Fertility Fertility Preservation Infertility Ovary Ovarian Oncofertility

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to learn about fertility preservation for pre-pubertal, peri-pubertal, and adult participants that are unable to pursue clinical standard of care fertility preservation such as egg (oocyte) and embryo cryopreservation. In addition, this study will provide research tissue for the following Specific Aims: 1. To optimize techniques for cryopreservation of ovarian tissues from patients at significant risk for infertility. 2. To investigate factors affecting successful maturation ovarian tissue. Participants will undergo a surgical procedure to remove an ovary (oophorectomy) to preserve their gonadal tissue for fertility preservation.

Official Title

Ovarian Tissue Cryopreservation for Fertility Preservation in Patients Facing Infertility-causing Diseases or Treatment Regimens

Quick Facts

Study Start:2011-01-13

Study Completion:2031-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05875155

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 39 Years

Sexes Eligible for Study:FEMALE

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Be female age less than 40 years old. * Unable or unwilling to make use of oocyte or embryo banking alone. * Be scheduled to undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy with risk of causing permanent and complete loss of subsequent ovarian function. * Or, have a medical condition or malignancy that requires removal of all or part of one or both ovaries. * Or, Have newly diagnosed or recurrent disease. Those who were not enrolled at the time of initial diagnosis (i.e., patients with recurrent disease) are eligible if they have not previously received therapy that is viewed as likely to result in complete and permanent loss of ovarian function. * Have two ovaries if undergoing elective removal of an ovary for fertility preservation only.	* Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent. * Diagnosed with an underlying medical condition that significantly increases their risk of complications from anesthesia and surgery.

Inclusion Criteria

Exclusion Criteria

* Be female age less than 40 years old.
* Unable or unwilling to make use of oocyte or embryo banking alone.
* Be scheduled to undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy with risk of causing permanent and complete loss of subsequent ovarian function.
* Or, have a medical condition or malignancy that requires removal of all or part of one or both ovaries.
* Or, Have newly diagnosed or recurrent disease. Those who were not enrolled at the time of initial diagnosis (i.e., patients with recurrent disease) are eligible if they have not previously received therapy that is viewed as likely to result in complete and permanent loss of ovarian function.
* Have two ovaries if undergoing elective removal of an ovary for fertility preservation only.

* Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent.
* Diagnosed with an underlying medical condition that significantly increases their risk of complications from anesthesia and surgery.

Contacts and Locations

Study Contact

Rachel Neelley, BA

CONTACT

4126417475

fertilitypreservation@upmc.edu

Principal Investigator

Kyle Orwig, PhD

PRINCIPAL_INVESTIGATOR

University of Pittsburgh/ University of Pittsburgh Medical Center

Study Locations (Sites)

Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213

United States

Collaborators and Investigators

Sponsor: University of Pittsburgh

Kyle Orwig, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh/ University of Pittsburgh Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2011-01-13

Study Completion Date2031-01

Study Record Updates

Study Start Date2011-01-13

Study Completion Date2031-01

Terms related to this study

Keywords Provided by Researchers

Fertility
Fertility Preservation
Infertility
Ovary
Ovarian
Oncofertility

Additional Relevant MeSH Terms

Cancer
Autoimmune Diseases